Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
03/1996
03/21/1996CA2199730A1 Protection of hemopoietic cells during chemotherapy or radiotherapy
03/21/1996CA2199719A1 Process for manufacture of a modified collagen-induced platelet aggregation inhibitor pallidipin
03/21/1996CA2199264A1 System and method of automatically generating chemical compounds with desired properties
03/21/1996CA2198478A1 Fibrinogen receptor antagonists
03/20/1996EP0702012A1 Substituted isoxazole sulfonamides and their use as endothelin antagonists
03/20/1996EP0701606A1 Method of enhancing thrombolysis
03/20/1996EP0701568A1 New peptide derivatives
03/20/1996EP0701455A1 Plasma-like solution
03/20/1996EP0701446A1 Hemoregulatory peptides
03/20/1996CN1119013A Hydroxymethyl furazane carboxylic acid derivatives and their use in the treatment of cardio-vascular conditions
03/20/1996CN1118690A Pills replenishing bone marrow
03/20/1996CN1031339C Process for preparation of heterocyclically substituted phenylacetic acid derivatives
03/19/1996US5500429 Cardiovascular
03/19/1996US5500413 Process for manufacture of 1-deamino-8-D-arginine vasopressin
03/19/1996US5500411 Method for treating thromboembolic conditions by inhibiting reocclusion via the use of multiple bolus administration of thrombolytically active proteins
03/19/1996CA2073012C Method for isolating factor viii
03/19/1996CA2071653C Method of preparing activated protein c
03/14/1996WO1996007657A1 Pyrimido[5,4-d]pyrimidines, drugs containing these compounds, their use, and process for preparing them
03/14/1996WO1996007397A2 Delivery of solid drug compositions
03/14/1996WO1996004378A3 Chimeric proteins and muteins of tissue factor pathway inhibitors tfpi and tfpi-2
03/13/1996EP0700999A2 Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide
03/13/1996EP0700684A2 Composition containing prothrombincomplex-concentrate and at least one additional component which activates the coagulation, as antidote for blood-anticoagulants
03/13/1996EP0700682A2 Medicament containing prothrombin for antagonizing blood-anticoagulents
03/13/1996EP0700440A1 Regulator of contact-mediated hemolysin
03/13/1996EP0700299A1 Oxygen-reduced aqueous solution of factor viii
03/13/1996EP0502962B1 Hirudinmuteins and their polyalkylene glycol conjugates
03/13/1996EP0502926B1 Anti-thrombotic peptides and pseudopeptides
03/13/1996EP0472657B1 Method and composition for the treatment of thrombosis in a mammal
03/12/1996US5498698 Megakaryocyte potentiator
03/12/1996US5498601 Rgd sequence
03/12/1996US5498599 Methods for stimulating platelet production
03/12/1996US5498499 Peptides and antibodies that inhibit platelet adhesion
03/07/1996WO1996006943A1 Cell cycle regulated repressor and dna element
03/07/1996WO1996006940A1 Genetic therapy of tumours with an endothelium cell-specific active substance which is dependent on the cell cycle
03/07/1996WO1996006939A1 Genetic therapy of diseases of the central nervous system with a cell-specific active substance which is dependent on the cell cycle
03/07/1996WO1996006933A1 Gene therapy for transplantation and inflammatory or thrombotic conditions
03/07/1996WO1996006928A1 A method of selecting pluripotent hematopoietic progenitor cells
03/07/1996WO1996006867A1 Method for controlling o-desulfation of heparin and compositions produced thereby
03/07/1996WO1996006849A1 Novel phosphane oxides, method of preparing them and drugs containing these compounds
03/07/1996WO1996006845A1 Substituted 9-alkyladenines
03/07/1996WO1996006840A1 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
03/07/1996WO1996006832A1 Novel 4-aminopyridazines, method of preparing them and drugs containing these compounds
03/07/1996WO1996006623A1 Antithrombotic and non-hemorrhagic heparin-based compositions, method for their preparation and therapeutic applications
03/07/1996DE4430757A1 Neue 4-Aminopyridazine, Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel New 4-Aminopyridazine, process for their preparation and pharmaceutical compositions containing them
03/07/1996DE4430755A1 Neue Phosphanoxide, Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel New phosphine oxides, processes for their preparation and pharmaceutical compositions containing them
03/07/1996CA2198908A1 Method for controlling o-desulfation of heparin and compositions produced thereby
03/07/1996CA2198722A1 Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications
03/07/1996CA2198474A1 Genetic therapy of diseases of the central nervous system with a cell-specific active substance which is dependent on the cell cycle
03/07/1996CA2198473A1 Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound
03/07/1996CA2198472A1 Genetic therapy of vascular diseases with a cell-specific active substance which is dependent on the cell cycle
03/07/1996CA2198366A1 Novel 4-aminopyridazines, processes for their production as well as pharmaceutical agents
03/07/1996CA2198365A1 Novel phosphane oxides, method of preparing them and drugs containing these compounds
03/07/1996CA2198080A1 Cell cycle regulated repressor and dna element
03/07/1996CA2197895A1 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
03/07/1996CA2197427A1 Gene therapy for transplantation and inflammatory or thrombotic conditions
03/06/1996EP0699764A1 A method of using eukaryotic expression vectors comprising the BK virus enhancer
03/06/1996EP0699438A2 Use of neurotensin antagonists for the preparation of diuretic drugs
03/06/1996EP0699210A1 Topical fibrinogen complex
03/06/1996EP0699075A1 Modified factor vii
03/06/1996EP0699074A1 Thrombin inhibitors
03/06/1996CN1118139A Fibrinogen receptor antagonists
03/06/1996CN1117874A Nasally administrable compositions
03/05/1996US5496851 Antiinflammatory, anticoagulants
03/05/1996US5496724 Genes encoding platelet aggregation inhibitors
03/05/1996CA1338122C Tissue factor inhibitor of coagulation
03/05/1996CA1338109C Pyridine derivatives and intermediates thereof
02/1996
02/29/1996WO1996006169A1 Human chemokine beta-9
02/29/1996WO1996006087A1 Bicyclic compounds
02/29/1996WO1996006078A1 N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists
02/29/1996WO1996006077A1 N-[2-(pyrrolidinyl-1)-1-phenylethyl]acetamides as kappa receptor antagonists
02/29/1996WO1996005860A1 A method of treating a patient with a biologically active compound
02/29/1996CA2198206A1 Human chemokine beta-9
02/28/1996EP0698616A1 Process for the preparation of a C1-esterase inhibitor (C1-1NH) concentrate and therapeutical use thereof
02/28/1996EP0698597A2 Cyclohexadiene derivatives
02/28/1996EP0698108A1 Adenoviral vectors of animal origin and use thereof in gene therapy
02/28/1996EP0698107A1 Gene therapy for haemophilia
02/28/1996EP0698094A1 Bmp-11 compositions
02/28/1996EP0698039A1 Peptides for suppression of myeloid progenitor cell proliferation and treatment of septic shock
02/28/1996EP0698031A1 SIALYL LE x ANALOGUES AS INHIBITORS OF CELLULAR ADHESION
02/28/1996EP0698023A1 Fibrinogen receptor antagonists
02/28/1996EP0697880A1 Inhibition of leukocyte adhesion
02/28/1996EP0697857A1 Hookworm anticoagulant
02/27/1996US5495023 Nitro compounds, process for preparation thereof and use thereof
02/27/1996US5495000 Anticoagulant peptides
02/27/1996US5494928 Indole derivatives
02/27/1996US5494921 Fibrinogen receptor antagonists
02/27/1996CA2156991A1 Compositions which are suitable for employment as antidotes to blood anticoagulants, and their use
02/27/1996CA2156990A1 Pharmaceutical which is suitable for employment as an antidote to blood anticoagulants, and its use
02/27/1996CA2155447A1 Substituted biphenyl isoxazole sulfonamides
02/27/1996CA2015738C Vitamin and mineral supplements
02/26/1996CA2156674A1 Cyclohexadiene derivatives
02/22/1996WO1996005194A1 Cyclic benzazepine urea derivatives with aggregation-inhibiting effect
02/22/1996WO1996005191A1 Natriuretic cyclic compounds
02/22/1996WO1996004930A1 Transferrin compositions to alleviate the side effects of cytotoxic drugs
02/22/1996WO1996004923A1 Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides
02/22/1996WO1996004916A1 Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
02/22/1996DE4429079A1 Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung Cyclic urea derivatives, medicaments containing these compounds and processes for their preparation
02/22/1996CA2197789A1 Cyclic urea derivatives, pharmaceutical compositions comprising these compounds and processes for their preparation
02/22/1996CA2197205A1 Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides
02/21/1996EP0697408A1 1 substituted-phenyl-oxazolidene-2-one derivatives and their use as adhesion-receptor antagonists
1 ... 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 ... 671